Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Acquisitions (2021 - 2022)

Historic Acquisitions for 10x Genomics (TXG) over the last 2 years, with Q4 2022 value amounting to $2.5 million.

  • 10x Genomics' Acquisitions changed N/A to $2.5 million in Q4 2022 from the same period last year, while for Dec 2023 it was $4.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.0 million for FY2022, which is 2661.9% down from last year.
  • Per 10x Genomics' latest filing, its Acquisitions stood at $2.5 million for Q4 2022.
  • Over the past 5 years, 10x Genomics' Acquisitions peaked at $5.5 million during Q1 2021, and registered a low of $1.5 million during Q3 2022.